HRCM
ITCI
Hood River Capital Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-615,161
| Closed | -$51.4M | – | 189 |
|
|
2024
Q4 | $51.4M | Buy |
615,161
+15,170
| +3% | +$1.27M | 0.76% | 50 |
|
|
2024
Q3 | $43.9M | Buy |
599,991
+112,473
| +23% | +$8.23M | 0.71% | 57 |
|
|
2024
Q2 | $33.4M | Buy |
+487,518
| New | +$33.4M | 0.69% | 56 |
|
|
2023
Q3 | – | Sell |
-839,130
| Closed | -$53.1M | – | 147 |
|
|
2023
Q2 | $53.1M | Buy |
839,130
+10,243
| +1% | +$649K | 1.58% | 21 |
|
|
2023
Q1 | $44.9M | Buy |
828,887
+35,216
| +4% | +$1.91M | 1.45% | 28 |
|
|
2022
Q4 | $42M | Buy |
793,671
+149,806
| +23% | +$7.93M | 1.53% | 22 |
|
|
2022
Q3 | $30M | Buy |
643,865
+11,877
| +2% | +$553K | 1.15% | 31 |
|
|
2022
Q2 | $36.1M | Buy |
631,988
+121,158
| +24% | +$6.92M | 1.43% | 19 |
|
|
2022
Q1 | $31.3M | Buy |
+510,830
| New | +$31.3M | 1.04% | 34 |
|